Long-term observation of Eosinophilic Granulomatosis With Polyangiitis
Longitudinal Protocol for Eosinophilic Granulomatosis With Polyangiitis
This study is trying to find new ways to track how Eosinophilic Granulomatosis With Polyangiitis affects people over time by looking at their health and collecting samples.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 700 (estimated) |
| Sex | All |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 13 sites (San Diego, California and 12 other locations) |
| Trial ID | NCT00315380 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on Eosinophilic Granulomatosis With Polyangiitis (EGPA), a rare immune disorder characterized by asthma, high eosinophil levels, and vasculitis. The study aims to identify new biological markers that can help assess disease activity and severity in patients with EGPA. Participants will undergo regular visits every six months or annually, during which blood and urine samples will be collected, and questionnaires will be administered to evaluate their health status and disease progression. The findings may enhance clinical care and inform future drug development for EGPA.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Eosinophilic Granulomatosis With Polyangiitis.
Not a fit: Patients who are unable to provide informed consent will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved monitoring and treatment strategies for patients with Eosinophilic Granulomatosis With Polyangiitis.
How similar studies have performed: Other studies have explored biomarkers in similar conditions, indicating potential for success in this novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study. Parent or guardian willing to provide informed consent, if applicable Exclusion Criteria: \- Inability to give informed consent and to sign the consent form
Where this trial is running
San Diego, California and 12 other locations
- University of California San Diego — San Diego, California, United States (Completed)
- National Jewish Health — Denver, Colorado, United States (Completed)
- Brigham and Women's Hospital — Boston, Massachusetts, United States (Completed)
- Mayo Clinic — Rochester, Minnesota, United States (Completed)
- Cleveland Clinic Foundation — Cleveland, Ohio, United States (Completed)
- University of Pennsylvania — Philadelphia, Pennsylvania, United States (Completed)
- University of Pittsburgh — Pittsburgh, Pennsylvania, United States (Completed)
- University of Utah — Salt Lake City, Utah, United States (Completed)
- St. Joseph's Healthcare — Hamilton, Ontario, Canada (Recruiting)
- Mount Sinai Hospital — Toronto, Ontario, Canada (Completed)
- medius KLINIK KIRCHHEIM — Kirchheim unter Teck, Germany (Recruiting)
- AOU Meyer IRCCS — Florence, Italy (Recruiting)
- Imperial College Healthcare NHS Trust/ Imperial College London — London, United Kingdom (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.